Issue Date: August 18, 2014
Mannkind Gets A Deal With Sanofi
The drug company MannKind has signed up Sanofi as a partner to sell Afrezza, the inhaled insulin it has long labored to get to market. FDA okayed the product in late June, fully five years after California-based MannKind applied for approval. The firms intend to launch Afrezza in the U.S. in early 2015.
Sanofi will pay MannKind $150 million up front, and loan it up to $175 million, to . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society